Gene Logic Establishes Drug Repositioning and Development Agreement with Merk Sereno
News Aug 24, 2007
Gene Logic Inc. has announced that it has entered into a drug repositioning and development agreement with Merck Serono, a division of Merck KGaA of Germany, to seek alternative development paths for several Merck Serono drug candidates. All of these drug candidates were discontinued or de-prioritized in clinical trials for reasons other than safety.
The agreement provides for payment to Gene Logic of success-based milestones and royalties similar to those paid for development-stage in-licensing deals, discounted to account for Merck Serono's contribution as the originator of the compound.
The agreement also provides Gene Logic the option to receive an exclusive license to any drug candidate for which Gene Logic identifies a new potential therapeutic use that Merck Serono chooses not to develop. If Gene Logic elects to obtain such a license, Merck Serono would be entitled to receive success-based milestone and royalty payments.
Gene Logic's Drug Repositioning Program seeks to find alternative development paths for drug candidates with good safety records that have been de-prioritized or discontinued in clinical trials. The program offers pharmaceutical partners an approach to bolster their pipelines with high-quality drug candidates that originated from their own R&D efforts.
Applying a diverse set of drug discovery technologies in parallel, Gene Logic's Drug Repositioning Program evaluates drug candidates for potential utility across a wide spectrum of disease indications.
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE